CA2407680A1 - Dendritic cell co-stimulator molecules - Google Patents
Dendritic cell co-stimulator molecules Download PDFInfo
- Publication number
- CA2407680A1 CA2407680A1 CA002407680A CA2407680A CA2407680A1 CA 2407680 A1 CA2407680 A1 CA 2407680A1 CA 002407680 A CA002407680 A CA 002407680A CA 2407680 A CA2407680 A CA 2407680A CA 2407680 A1 CA2407680 A1 CA 2407680A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- polypeptide
- cell
- subject
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 50
- 229920001184 polypeptide Polymers 0.000 claims abstract 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 48
- 210000004027 cell Anatomy 0.000 claims abstract 33
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 28
- 239000012634 fragment Substances 0.000 claims abstract 25
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims abstract 23
- 230000004927 fusion Effects 0.000 claims abstract 21
- 238000000034 method Methods 0.000 claims abstract 21
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims abstract 16
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims abstract 16
- 229960005486 vaccine Drugs 0.000 claims abstract 11
- 239000013604 expression vector Substances 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract 8
- 230000001939 inductive effect Effects 0.000 claims abstract 7
- 230000004044 response Effects 0.000 claims abstract 5
- 230000000139 costimulatory effect Effects 0.000 claims abstract 2
- 230000003389 potentiating effect Effects 0.000 claims abstract 2
- 150000007523 nucleic acids Chemical class 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 23
- 108091007433 antigens Proteins 0.000 claims 23
- 102000036639 antigens Human genes 0.000 claims 23
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 230000007503 antigenic stimulation Effects 0.000 claims 16
- 230000028993 immune response Effects 0.000 claims 16
- 230000001965 increasing effect Effects 0.000 claims 16
- 230000005867 T cell response Effects 0.000 claims 11
- 210000004881 tumor cell Anatomy 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 5
- 230000014509 gene expression Effects 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 210000004748 cultured cell Anatomy 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 244000005700 microbiome Species 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 230000001681 protective effect Effects 0.000 claims 3
- 238000003259 recombinant expression Methods 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241000527994 Cyclotella gamma Species 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000004186 co-expression Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
A costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising thi s DNA. B7-DC protein, fragments, fusion polypeptides/proteins and other functional derivatives, and transformed cells expressing B7-DC are useful in vaccine compositions and methods. Compositions and methods are disclosed for inducing potent T cell mediated responses that can be harnessed for anti-tum or and anti-viral immunity.
Claims (68)
1.~An isolated nucleic acid molecule that encodes a mammalian protein termed B7-DC that is selectively expressed on dendritic cells as compared to activated macrophages.
2. ~The nucleic acid molecule of claim 1 that comprises a nucleotide sequence selected from SEQ ID NO: 1 or SEQ ID NO:5.
3. ~An isolated nucleic acid molecule that hybridizes with the nucleic acid molecule of claim 1 or 2 under stringent hybridization conditions.
4. ~The nucleic acid molecule of claim 2 that comprises the nucleotide sequence SEQ ID NO:1.
5. ~The nucleic acid molecule of any of claims 1-4 that encodes a protein having an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4 or encodes a biologically active fragment, homologue or other functional derivative of said protein.
6. ~The nucleic acid molecule of claim 6 that encodes said protein having the sequence SEQ ID NO:2 or encodes said biologically active fragment, homologue or other functional derivative of SEQ ID NO:2.
7. ~A fragment of the nucleic acid molecule of any of claims 5 or 6 that encodes all or part of the extracellular domain of said B7-DC protein.
8. ~The nucleic acid molecule of claim 5 that encodes a B7-DC fusion polypeptide, which molecule comprises:
(a) ~a first nucleic acid sequence encoding a first polypeptide that is all or a part of a B7-DC protein SEQ ID NO: 2 or SEQ ID NO:4;
(b) ~optionally, fused in frame with the first nucleic acid sequence, a linker nucleic acid sequence encoding a linker peptide; and (c) ~a second nucleic acid sequence that is linked in frame to said first nucleic acid sequence or to said linker nucleic acid sequence and that encodes a second polypeptide.
(a) ~a first nucleic acid sequence encoding a first polypeptide that is all or a part of a B7-DC protein SEQ ID NO: 2 or SEQ ID NO:4;
(b) ~optionally, fused in frame with the first nucleic acid sequence, a linker nucleic acid sequence encoding a linker peptide; and (c) ~a second nucleic acid sequence that is linked in frame to said first nucleic acid sequence or to said linker nucleic acid sequence and that encodes a second polypeptide.
9. ~The nucleic acid molecule of claim 8 wherein said second polypeptide consists of one or more domains of an Ig heavy chain constant region.
10. ~The nucleic acid molecule of claim 11 wherein said second polypeptide consists of two domains of a human IgG constant region.
11. ~An expression vector comprising the nucleic acid of any of claims 1-10 operatively linked to:
(a) a promoter and (b) optionally, additional regulatory sequences that regulate expression of said nucleic acid in a eukaryotic cell.
(a) a promoter and (b) optionally, additional regulatory sequences that regulate expression of said nucleic acid in a eukaryotic cell.
12. ~The expression vector of claim 11 which is a plasmid.
13. ~The expression vector of claim 11 which is a viral vector.
14. ~A vector composition comprising (a) ~a first recombinant expression vector having incorporated in its nucleic acid a nucleotide sequence encoding an antigen of interest against which an immune response is to be induced; and (b) ~a second recombinant expression vector having incorporated in its nucleic acid one or more nucleotide sequences encoding a co-stimulator polypeptide, at least one of which co-stimulator polypeptides is B7-DC, or is a biologically active fragment, homologue or other functional derivative thereof, wherein the expression vectors are able to co-infect or co-transfect a host cell resulting in co-expression of the antigen and the costimulator polypeptide, fragment, homologue or derivative.
15. ~The vector of claim 14 wherein said second vector comprises SEQ ID NO:1 or SEQ ID NO:5.
16. ~The vector of claim 14 or 15 wherein said second vector comprises SEQ ID
NO:1.
NO:1.
17. ~A cell transformed or transfected with the nucleic acid molecule of any of claims 1-
18. ~A cell transformed or transfected with the expression vector of any of claims claim 1-16.
19. The cell of claim 19 which is a mammalian cell.
20. The cell of claim 19 which is a human cell.
21. The cell of claim 19 which is a dendritic cell or a progenitor thereof.
22. The cell of claim 19 which is a tumor cell.
23. An isolated mammalian tumor cell transfected with an exogenous nucleic acid molecule encoding a mammalian B7-DC protein or a biologically active fragment, homologue or other functional derivative thereof, such that when said protein, fragment, homologue or derivative is expressed by said tumor cell, and said tumor cell is contacted with T cells (i) said B7-DC protein, fragment, homologue or derivative binds to said T
cells; and (ii) said tumor cell costimulates said T cells to proliferate and/or to produce and secrete cytokines.
cells; and (ii) said tumor cell costimulates said T cells to proliferate and/or to produce and secrete cytokines.
24. The tumor cell of claim 23 wherein said exogenous nucleic acid molecule comprises SEQ ID NO:1, SEQ ID NO:5 or a fragment of said sequence.
25. A polypeptide that is selectively expressed on dendritic cells as compared to activated macrophages and has the following functional properties:
(a) binds to a binding partner on T cells; and (b) costimulates T cells to proliferate and/or to produce and secrete cytokines.
(a) binds to a binding partner on T cells; and (b) costimulates T cells to proliferate and/or to produce and secrete cytokines.
26. The polypeptide, fragment, homologue or functional derivative of claim 25 encoded by a nucleic acid molecule having the sequence SEQ ID NO:1 or SEQ ID
NO:5, or a fragment, homologue or equivalent of said nucleic acid molecule.
NO:5, or a fragment, homologue or equivalent of said nucleic acid molecule.
27. The polypeptide of claim 26 having the amino acid sequence SEQ ID N0:2 or SEQ ID NO:4, or a fragment, homologue or equivalent of said polypeptide.
28. A polypeptide or a biologically active fragment, homologue or other functional derivative of said polypeptide produced by recombinant expression of the nucleic acid of any of claims 1 - 10.
29. The polypeptide of any of claims 25-28 comprising the extracellular domain of the B7-DC protein, which domain comprises amino acid residues 26-221 of SEQ ID
NO:2 or SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative of said domain.
NO:2 or SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative of said domain.
30. The polypeptide of any of claims 25-28 consisting essentially of the extracellular domain of B7-DC which domain includes amino acid residues 26-221of SEQ ID NO:2 or SEQ
ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative of residues 26-221.
ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative of residues 26-221.
31. A B7-DC fusion polypeptide having a first fusion partner comprising all or a part of a B7-DC protein which (i) is fused directly to a second polypeptide or, (ii) optionally, is fused to a linker peptide sequence that is fused to said second polypeptide.
32. A B7-DC fusion polypeptide comprising the polypeptide of any of claims claim 25-30 fused to a second polypeptide.
33. The fusion polypeptide of claim 32, that binds to a binding partner molecule on T
cells and co-stimulates said T cells in the presence of an adequate stimulus to the T cell receptor.
cells and co-stimulates said T cells in the presence of an adequate stimulus to the T cell receptor.
34. The fusion polypeptide of claim 33 wherein said binding partner molecule is PD-1.
35. The fusion polypeptide of any of claims 31-33 wherein said second polypeptide is one or more domains of an Ig heavy chain constant region.
36. The fusion polypeptide of any of claims 31-35 wherein said first fusion partner comprises amino acids 26-221 of SEQ ID NO:2 or of SEQ ID NO:4, or a co-stimulatory fragment, homologue or other functional derivative thereof.
37. The fusion polypeptide of claim 36 wherein said first fusion partner comprises amino acids 26-221 of SEQ ID NO:2, or a co-stimulatory fragment, homologue or other functional derivative thereof.
38. The fusion polypeptide of claim 35 wherein said polypeptide has an amino acid sequence corresponding to the hinge, CH2 and CH3 regions of a human immunoglobulin C.gamma.1 chain.
39. A dimeric or trimeric fusion polypeptide which is a tandemly linked dimer or trimer of the fusion polypeptide of any of claims 31-38.
40. The fusion polypeptide of any of claims 31 - 38, comprising a linear multimer of two or more repeats of monomers of said first fusion partner linked end to end, directly or with a linker sequences present between said monomer repeats.
41. An antibody that is specific for an epitope of a B7-DC protein, which epitope is not present in a known member of a B7 family protein.
42. The antibody of claim 41 wherein said epitope is a linear or conformational epitope of a polypeptide of SEQ ID NO:2 or SEQ ID NO:4.
43. The antibody of claim 42 wherein said epitope is a linear or conformational epitope of a polypeptide of SEQ ID NO:2.
44. The antibody of any of claims 41-42 that is a monoclonal antibody.
45. The antibody of claim 43 that is a human or humanized monoclonal antibody.
46. A method of identifying or quantitating cells expressing a B7-DC
polypeptide on their surface in a cell population, comprising (a) contacting cells of said population with the antibody of any of claims 41-45, so that said antibody binds to cells expressing said epitope;
(b) assessing the presence of, or quantitating the number of, cells to which said antibody is bound.
polypeptide on their surface in a cell population, comprising (a) contacting cells of said population with the antibody of any of claims 41-45, so that said antibody binds to cells expressing said epitope;
(b) assessing the presence of, or quantitating the number of, cells to which said antibody is bound.
47. A method of isolating cells expressing a B7-DC polypeptide on their surface from a cell population, comprising (a) contacting cells of said population with the antibody of any of claims 41-45, so that said antibody binds to cells expressing said epitope;
(b) positively selecting cells to which said antibody has bound or negatively selecting cells to which said antibody has not bound, thereby isolating said cells.
(b) positively selecting cells to which said antibody has bound or negatively selecting cells to which said antibody has not bound, thereby isolating said cells.
48. A method of detecting the presence or quantitating a B7-DC polypeptide, fragment or homologue in a sample, comprising the steps of:
(a) contacting the sample with the antibody of any of claims 41-45, such that the antibody binds to any polypeptides or fragments bearing said epitope;
(b) detecting the presence of, or quantitating the polypeptides or fragments bound to said antibody.
(a) contacting the sample with the antibody of any of claims 41-45, such that the antibody binds to any polypeptides or fragments bearing said epitope;
(b) detecting the presence of, or quantitating the polypeptides or fragments bound to said antibody.
49. A method of inducing or increasing the expression of a B7-DC polypeptide in an antigen presenting cell or a progenitor thereof to increase the ability of said cell to co-stimulate T cells in vitro or in vivo in the presence of an adequate stimulus to the T
cell receptor, comprising transforming or transfecting said antigen presenting cell or progenitor cell with the expression vector of any of claims 11-13, such that said expression of the B7-DC polypeptide is induced or increased on said cells.
cell receptor, comprising transforming or transfecting said antigen presenting cell or progenitor cell with the expression vector of any of claims 11-13, such that said expression of the B7-DC polypeptide is induced or increased on said cells.
50. A method of inducing or increasing the expression of a B7-DC polypeptide in an antigen presenting cell or a progenitor thereof to increase the ability of said cell to co-stimulate T cells in vitro or in vivo in the presence of an adequate stimulus to the T
cell receptor, comprising transforming or transfecting said antigen presenting cell or progenitor cell with the expression vector of any of claims 11-13, such that said expression of the B7-DC polypeptide is induced or increased on said cells.
cell receptor, comprising transforming or transfecting said antigen presenting cell or progenitor cell with the expression vector of any of claims 11-13, such that said expression of the B7-DC polypeptide is induced or increased on said cells.
51. The method of claim 49 or 50 wherein said antigen presenting cells are dendritic cells and said progenitors are dendritic cell progenitors.
52. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of cells according to any of claims 17-24, in conjunction with an antigen, wherein said cells are effective to increase the T cell response of said subject to said antigenic stimulation.
53. A method for increasing the T cell response of a mammalian subject to antigenic stimulation with a tumor-associated antigen, comprising administering to said subject an effective amount of tumor cells according to any of claims 22 -24, wherein said tumor cells express said antigen, said administration of said tumor cells being effective to increase the T cell response of said subject to said tumor antigen stimulation.
54. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of a polypeptide, fragment, homologue or functional derivative according to any of claims 25-30 in conjunction with an antigen, wherein the administration of said polypeptide is effective to increase the T cell response of said subject to said antigenic stimulation.
55. A method for increasing the T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of a fusion polypeptide according to any of claims 31-40, in conjunction with an antigen, wherein the administration of said polypeptide is effective to increase the T cell response of said subject to said antigenic stimulation.
56. A method for inhibiting a T cell response of a mammalian subject to antigenic stimulation, comprising administering to said subject an effective amount of an antibody according to any of claims 41-45, wherein the administration of said antibody is effective to block stimulation of T cells or to eliminate antigen-reactive T cells, thereby inhibiting the T cell response.
57. The method of claim 56 wherein said T cell response is directed to a tissue transplant or to an autoantigen such that said method inhibits transplant rejection or an autoimmune reaction.
58. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:
(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
(b) contacting said T cells ex vivo with an effective amount of cells according to any of claim 17-24, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and (c) administering said T cells of step (b) to said subject, thereby increasing said immune response of said subject.
(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
(b) contacting said T cells ex vivo with an effective amount of cells according to any of claim 17-24, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and (c) administering said T cells of step (b) to said subject, thereby increasing said immune response of said subject.
59. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:
(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
(b) contacting said T cells ex vivo with an effective amount of cells according to any of claims 17-24, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and (c) administering said T cells of step (b) to said subject, thereby increasing said immune response of said subject.
(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
(b) contacting said T cells ex vivo with an effective amount of cells according to any of claims 17-24, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and (c) administering said T cells of step (b) to said subject, thereby increasing said immune response of said subject.
60. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:
(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
(b) contacting said T cells ex vivo with an effective amount of the polypeptide, fragment, homologue or functional derivative of any of claims 25-30, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and (c) administering said T cells of step (b) to said subject, thereby increasing said immune response of said subject.
(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
(b) contacting said T cells ex vivo with an effective amount of the polypeptide, fragment, homologue or functional derivative of any of claims 25-30, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and (c) administering said T cells of step (b) to said subject, thereby increasing said immune response of said subject.
61. A method for increasing the immune response of a mammalian subject to antigenic stimulation comprising:
(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
(b) contacting said T cells ex vivo with an effective amount of a the fusion polypeptide of any of claims 31-40, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and (c) administering said T cells of step (b) to said subject, thereby increasing said immune response of said subject.
(a) obtaining T cells from (i) said subject, (ii) an immunologically compatible donor for said subject, or (iii) an immunologically compatible or acceptable cultured cell line;
(b) contacting said T cells ex vivo with an effective amount of a the fusion polypeptide of any of claims 31-40, wherein said contacting is effective to increase the response of said T cells to antigenic stimulation; and (c) administering said T cells of step (b) to said subject, thereby increasing said immune response of said subject.
62. A vaccine composition useful for inducing a protective immune response against an antigen associated with a pathogenic cell or microorganism, comprising (a) the transformed or transfected cells of any of claims 17-24 which optionally express said antigen;
(b) if the cells of (a) do not express said antigen, an additional source of said antigen;
(c) optionally, a general immunostimulatory agent or adjuvant; and (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).
(b) if the cells of (a) do not express said antigen, an additional source of said antigen;
(c) optionally, a general immunostimulatory agent or adjuvant; and (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).
63. A vaccine composition useful for inducing a protective immune response against an antigen associated with a pathogenic cell or microorganism, comprising (a) a source of antigen to which an immune response is desired;
(b) the polypeptide, fragment, homologue or functional derivative of any of claims 25-30;
(c) optionally, a general immunostimulatory agent or adjuvant; and (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).
(b) the polypeptide, fragment, homologue or functional derivative of any of claims 25-30;
(c) optionally, a general immunostimulatory agent or adjuvant; and (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).
64. A vaccine composition useful for inducing a protective immune response against an antigen associated with a pathogenic cell or microorganism, comprising (a) a source of antigen to which an immune response is desired;
(b) the fusion polypeptide of any of claims 31-40;
(c) optionally, a general immunostimulatory agent or adjuvant; and (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).
(b) the fusion polypeptide of any of claims 31-40;
(c) optionally, a general immunostimulatory agent or adjuvant; and (d) a pharmaceutically and immunologically acceptable excipient or carrier for (a), b) and (c).
65. A co-stimulatory composition for use with an antigen or a vaccine to increase the immunogenicity of the antigen or vaccine, comprising:
(a) the polypeptide, fragment, homologue or functional derivative of any of claims 25-30; and (b) a pharmaceutically and immunologically acceptable excipient or carrier.
(a) the polypeptide, fragment, homologue or functional derivative of any of claims 25-30; and (b) a pharmaceutically and immunologically acceptable excipient or carrier.
66. A co-stimulatory composition for use with an antigen or a vaccine to increase the immunogenicity of the antigen or vaccine, comprising:
(a) the fusion polypeptide of any of claims 31-40; and (b) a pharmaceutically and immunologically acceptable excipient or carrier.
(a) the fusion polypeptide of any of claims 31-40; and (b) a pharmaceutically and immunologically acceptable excipient or carrier.
67. A method for inducing or enhancing an immune response to an antigen in a mammalian subject comprising administering to said subject an effective amount of the vaccine composition of any of claims 62-64.
68. A method for potentiating an immune response to an antigen or a vaccine in a mammalian subject, comprising administering to said subject, in combination with said antigen or vaccine, the costimulatory composition of claim 65 or 66.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20058000P | 2000-04-28 | 2000-04-28 | |
US60/200,580 | 2000-04-28 | ||
US24016900P | 2000-10-13 | 2000-10-13 | |
US60/240,169 | 2000-10-13 | ||
US09/794,210 | 2001-02-28 | ||
US09/794,210 US7030219B2 (en) | 2000-04-28 | 2001-02-28 | B7-DC, Dendritic cell co-stimulatory molecules |
PCT/US2001/013430 WO2001083750A2 (en) | 2000-04-28 | 2001-04-27 | Dendritic cell co-stimulator molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2407680A1 true CA2407680A1 (en) | 2001-11-08 |
CA2407680C CA2407680C (en) | 2012-02-21 |
Family
ID=26895892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2407680A Expired - Fee Related CA2407680C (en) | 2000-04-28 | 2001-04-27 | Dendritic cell co-stimulator molecules |
Country Status (14)
Country | Link |
---|---|
US (7) | US7030219B2 (en) |
EP (1) | EP1280900B8 (en) |
JP (2) | JP4987208B2 (en) |
KR (1) | KR100884766B1 (en) |
CN (1) | CN102199216A (en) |
AT (1) | ATE437228T1 (en) |
AU (2) | AU2001255700C1 (en) |
CA (1) | CA2407680C (en) |
DE (1) | DE60139311D1 (en) |
DK (1) | DK1280900T3 (en) |
ES (1) | ES2330506T3 (en) |
HK (1) | HK1111726A1 (en) |
MX (1) | MXPA02010670A (en) |
WO (1) | WO2001083750A2 (en) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8128922B2 (en) * | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
EP1892251A3 (en) * | 2000-06-06 | 2008-12-31 | Brystol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
ATE385504T1 (en) | 2000-06-06 | 2008-02-15 | Bristol Myers Squibb Co | NUCLEIC ACIDS AND POLYPEPTIDES RELATED TO B7 AND THEIR USES FOR IMMUNE MODULATION |
EP1320599A2 (en) | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 molecules: pd-1 ligands and uses therefor |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
CA2417214C (en) * | 2000-08-03 | 2016-06-21 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
US20030180309A1 (en) * | 2001-01-08 | 2003-09-25 | Baum Peter R. | Human B7 polypeptides |
US7414032B2 (en) | 2001-06-25 | 2008-08-19 | Immunofrontier, Inc. | Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL |
DK2206517T3 (en) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
US7052694B2 (en) * | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
US20040247578A1 (en) * | 2002-10-15 | 2004-12-09 | University Of Pittsburgh Of Commonwealth System Of Higher Education | Methods and reagents for inducing immunity |
DE60327948D1 (en) * | 2002-12-24 | 2009-07-23 | Immunofrontier Inc | POLYNUCLEOTIDE-CONTAINING VACCINES |
US20070026076A1 (en) * | 2003-02-24 | 2007-02-01 | Tzyy-Choou Wu | Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins |
EP1644048B1 (en) * | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
US20070196335A1 (en) * | 2004-02-09 | 2007-08-23 | The Johns Hopkins University | Immune Modulation By Regulating Expression Of The "Minor" Gene In Immune Dendritic Cells |
CA2572098C (en) * | 2004-06-30 | 2015-01-27 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
US7501119B2 (en) | 2004-06-30 | 2009-03-10 | Mayo Foundation For Medical Education And Research | Methods and molecules for modulating an immune response |
US20060099203A1 (en) * | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
HUE039237T2 (en) | 2004-10-06 | 2018-12-28 | Mayo Found Medical Education & Res | B7-h1 and pd-1 in treatment of renal cell carcinoma |
AU2005322960A1 (en) * | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines |
JP2008528004A (en) * | 2005-01-26 | 2008-07-31 | ザ ジョンズ ホプキンス ユニバーシティー | Anticancer DNA vaccine using plasmid encoding mutant oncoprotein antigen and calreticulin |
DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
NZ568015A (en) | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to O8E |
WO2007082154A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
WO2007082144A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
EP1997887B1 (en) * | 2006-03-03 | 2013-09-04 | Ono Pharmaceutical Co., Ltd. | Multimer of extracellular domain of cell surface functional molecule |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
US20100330105A1 (en) * | 2006-08-22 | 2010-12-30 | John Hopkins University | Anticancer Combination Therapies |
CN105056226A (en) * | 2006-12-27 | 2015-11-18 | 埃默里大学 | Compositions and methods for the treatment of infections and tumors |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080260765A1 (en) * | 2007-03-15 | 2008-10-23 | Johns Hopkins University | HPV DNA Vaccines and Methods of Use Thereof |
CN101784564B (en) * | 2007-07-13 | 2014-07-02 | 约翰霍普金斯大学 | B7-DC variants |
WO2009111315A2 (en) * | 2008-02-29 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Methods for reducing granulomatous inflammation |
ES2460899T3 (en) | 2008-03-03 | 2014-05-14 | The University Of Miami | Immunotherapy based on allogenic cancer cells |
US20090285861A1 (en) * | 2008-04-17 | 2009-11-19 | Tzyy-Choou Wu | Tumor cell-based cancer immunotherapeutic compositions and methods |
KR20110074850A (en) * | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 antagonists and methods of use thereof |
DK2350129T3 (en) | 2008-08-25 | 2015-08-31 | Amplimmune Inc | PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF |
DK2370593T3 (en) | 2008-11-28 | 2016-07-04 | Univ Emory | A method for determining the effect of PD-1 Antagonists |
SG10201708690SA (en) * | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
US8771667B2 (en) * | 2009-09-18 | 2014-07-08 | Cornell University | Tctex-1 regulatory sequence as stem cell marker |
RU2619187C2 (en) * | 2012-12-05 | 2017-05-12 | Тевакс Дженетикс Вэксин Ко., Лтд. | Fusion proteins for application as immunogenic amplifying agents to induce antigen-specific t-cell response |
CN103965363B (en) * | 2013-02-06 | 2021-01-15 | 上海白泽生物科技有限公司 | Fusion protein efficiently combined with PD-1 and VEGF, coding sequence and application thereof |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
EP3470081A1 (en) | 2013-10-01 | 2019-04-17 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
CN103923934B (en) * | 2014-03-22 | 2016-11-02 | 复旦大学 | A kind of engineered protein with immune negative regulation effect and preparation method and application |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
CN106999548A (en) * | 2014-07-14 | 2017-08-01 | 昆士兰医学研究所理事会 | galactose agglutinin immunotherapy |
EP3171896A4 (en) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Targeting dna-pkcs and b7-h1 to treat cancer |
EP3659621A1 (en) | 2014-09-13 | 2020-06-03 | Novartis AG | Combination therapies for cancer |
US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
LT3283508T (en) | 2015-04-17 | 2021-07-12 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
BR112018000768A2 (en) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anti-pd-1 antibodies, activatable anti-pd-1 antibodies and methods of use |
AU2016328279A1 (en) | 2015-09-24 | 2018-05-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
SG11201808783XA (en) | 2016-04-15 | 2018-11-29 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
CN109843931A (en) * | 2016-08-11 | 2019-06-04 | 昆士兰医学研究所理事会 | Immunomodulatory compounds |
WO2018170023A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
US20190367568A1 (en) * | 2018-02-05 | 2019-12-05 | Nantbio, Inc. | Calreticulin and fusion proteins |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US561310A (en) * | 1896-06-02 | Fare register and indicator | ||
US4272398A (en) | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5155020A (en) | 1989-03-08 | 1992-10-13 | Health Research Inc. | Recombinant poxvirus host range selection system |
US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
EP0318512B1 (en) | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
US4861627A (en) | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
US6699475B1 (en) | 1987-09-02 | 2004-03-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
EP0325224B1 (en) | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
US5175099A (en) | 1989-05-17 | 1992-12-29 | Research Corporation Technologies, Inc. | Retrovirus-mediated secretion of recombinant products |
US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JP3068180B2 (en) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | Generation of heterologous antibodies |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5204243A (en) | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2086325C (en) | 1990-07-02 | 2010-10-05 | Peter S. Linsley | Ligand for cd28 receptor on b cells and methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE185601T1 (en) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | METHOD FOR PRODUCING SPECIFIC BONDING PAIRS |
IE920206A1 (en) | 1991-01-24 | 1992-07-29 | Cytel Corp | Monoclonal antibodies to elam-1 and their uses |
WO1992016192A1 (en) | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
DE69228606T2 (en) | 1991-07-03 | 1999-06-24 | Kanebo Ltd | METHOD AND DEVICE FOR PRODUCING A THERMOPLASTIC POLYURETHANE ELASTOMER |
AU2880192A (en) | 1991-10-21 | 1993-05-21 | Sphinx Pharmaceuticals Corporation | 2-aminopropan-1,3-diol chemotherapeutic agents |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (en) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5861310A (en) | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US5942607A (en) | 1993-07-26 | 1999-08-24 | Dana-Farber Cancer Institute | B7-2: a CTLA4/CD28 ligand |
AU7526894A (en) | 1993-08-16 | 1995-03-14 | Arch Development Corporation | B7-2: ctla4/cd28 counter receptor |
DE4329503A1 (en) | 1993-09-01 | 1995-03-02 | Galenik Labor Freiburg Gmbh | Pharmaceutical preparations for the targeted treatment of Crohn's disease and ulcerative colitis |
JP3926839B2 (en) | 1993-09-14 | 2007-06-06 | エピミューン,インコーポレイティド | Modification of immune response using universal DR-binding peptides |
AU8083594A (en) | 1993-10-19 | 1995-05-08 | Scripps Research Institute, The | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5675848A (en) | 1995-10-18 | 1997-10-14 | Mallinckrodt Medical, Inc. | Inflatable blanket having perforations of different sizes |
CA2234685A1 (en) | 1995-11-10 | 1997-05-15 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
EP0871747A1 (en) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunostimulation mediated by gene-modified dendritic cells |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
AU737910B2 (en) | 1997-01-31 | 2001-09-06 | Regents Of The University Of California, The | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
US20060223088A1 (en) | 1997-03-07 | 2006-10-05 | Rosen Craig A | Human secreted proteins |
US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
DE69930630T2 (en) | 1998-06-10 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | B2 microglobulin fusion proteins and high affinity variants |
US6468546B1 (en) | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
AU3007200A (en) | 1999-02-26 | 2000-09-14 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
WO2000055375A1 (en) | 1999-03-17 | 2000-09-21 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
IL145731A0 (en) * | 1999-04-02 | 2002-07-25 | Corixa Corp | A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same |
CA2377513A1 (en) | 1999-06-25 | 2001-01-04 | Universitat Zurich | Hetero-associating coiled-coil peptides |
WO2001001137A1 (en) | 1999-06-30 | 2001-01-04 | Children's Medical Center Corporation | Fusion protein and uses thereof |
EP1074617A3 (en) | 1999-07-29 | 2004-04-21 | Research Association for Biotechnology | Primers for synthesising full-length cDNA and their use |
PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
EP1244683A4 (en) | 1999-11-12 | 2005-01-12 | Human Genome Sciences Inc | 21 human secreted proteins |
US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
ATE369359T1 (en) | 2000-02-15 | 2007-08-15 | Sugen Inc | PYRROLE SUBSTITUTED INDOLIN-2-ONE PROTEIN KINASE INHIBITORS |
WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
CA2747325A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
ATE385504T1 (en) | 2000-06-06 | 2008-02-15 | Bristol Myers Squibb Co | NUCLEIC ACIDS AND POLYPEPTIDES RELATED TO B7 AND THEIR USES FOR IMMUNE MODULATION |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
JP2003535907A (en) | 2000-06-22 | 2003-12-02 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Method for promoting antibody-induced cell lysis and treating cancer |
EP1320599A2 (en) * | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 molecules: pd-1 ligands and uses therefor |
CA2406649A1 (en) * | 2000-06-30 | 2002-01-10 | Human Genome Sciences, Inc. | B7-like polynucleotides, polypeptides, and antibodies |
KR20020004362A (en) | 2000-07-05 | 2002-01-16 | 김권 | Polyolefin resin composition containing natural anti-oxidant and thermo-stabilizing agent without harmful effect to the human body |
EP1299606B1 (en) | 2000-07-05 | 2006-10-04 | Vogue Pool Products | Above ground swimming pool support structure |
US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
ATE532860T1 (en) | 2000-09-20 | 2011-11-15 | Amgen Inc | B7-LIKE MOLECULES AND THEIR APPLICATIONS |
US7182942B2 (en) | 2000-10-27 | 2007-02-27 | Irx Therapeutics, Inc. | Vaccine immunotherapy for immune suppressed patients |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
CA2433313A1 (en) | 2000-12-19 | 2002-07-25 | Curagen Corporation | Polypetides and nucleic acids encoding same |
US6562576B2 (en) | 2001-01-04 | 2003-05-13 | Myriad Genetics, Inc. | Yeast two-hybrid system and use thereof |
US20030180309A1 (en) | 2001-01-08 | 2003-09-25 | Baum Peter R. | Human B7 polypeptides |
US6743619B1 (en) | 2001-01-30 | 2004-06-01 | Nuvelo | Nucleic acids and polypeptides |
WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
EP2388590A1 (en) | 2001-04-02 | 2011-11-23 | Dana Farber Cancer Institute | PD-1, a receptor for B7-4, and uses thereof |
AR036993A1 (en) | 2001-04-02 | 2004-10-20 | Wyeth Corp | USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS |
US20060084794A1 (en) | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
DK1446478T3 (en) | 2001-10-19 | 2008-06-02 | Zymogenetics Inc | Dimerized growth factor as well as materials and processes for making them |
JP4488740B2 (en) | 2001-11-13 | 2010-06-23 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Agents that modulate immune cell activation and methods of use thereof |
US7164500B2 (en) | 2002-01-29 | 2007-01-16 | Hewlett-Packard Development Company, L.P. | Method and apparatus for the automatic generation of image capture device control marks |
SI1503794T1 (en) | 2002-04-12 | 2012-09-28 | Medarex Inc | Methods of treatement using ctla-4 antibodies |
DK2206517T3 (en) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
US7052694B2 (en) | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
WO2004014322A2 (en) | 2002-08-12 | 2004-02-19 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
EP2270051B1 (en) | 2003-01-23 | 2019-05-15 | Ono Pharmaceutical Co., Ltd. | Antibody specific for human PD-1 and CD3 |
EP1597273A2 (en) | 2003-02-27 | 2005-11-23 | TheraVision GmbH | Soluble ctla4 polypeptides and methods for making the same |
EP2251352A1 (en) | 2003-08-07 | 2010-11-17 | ZymoGenetics, L.L.C. | Homogeneous preparations of IL-28 and IL-29 |
EP1732946B1 (en) | 2004-03-08 | 2011-07-27 | ZymoGenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
US20060099203A1 (en) | 2004-11-05 | 2006-05-11 | Pease Larry R | B7-DC binding antibody |
US20070166281A1 (en) | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
HUE039237T2 (en) | 2004-10-06 | 2018-12-28 | Mayo Found Medical Education & Res | B7-h1 and pd-1 in treatment of renal cell carcinoma |
EP2366717A3 (en) | 2004-10-29 | 2011-12-14 | University of Southern California | Combination Cancer Immunotherapy with Co-Stimulatory Molecules |
DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
GB0519303D0 (en) | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
US20070231344A1 (en) | 2005-10-28 | 2007-10-04 | The Brigham And Women's Hospital, Inc. | Conjugate vaccines for non-proteinaceous antigens |
WO2007065167A1 (en) | 2005-12-02 | 2007-06-07 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
EP1954311A4 (en) | 2005-12-07 | 2009-12-23 | Medarex Inc | Ctla-4 antibody dosage escalation regimens |
WO2007067681A2 (en) | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Immunostimulatory compositions and methods |
CA2663521A1 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
WO2008037080A1 (en) | 2006-09-29 | 2008-04-03 | Universite De Montreal | Methods and compositions for immune response modulation and uses thereof |
CN105056226A (en) | 2006-12-27 | 2015-11-18 | 埃默里大学 | Compositions and methods for the treatment of infections and tumors |
WO2008100562A2 (en) | 2007-02-14 | 2008-08-21 | Medical College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
CN101784564B (en) | 2007-07-13 | 2014-07-02 | 约翰霍普金斯大学 | B7-DC variants |
WO2009023566A2 (en) | 2007-08-09 | 2009-02-19 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
EP2195347A1 (en) | 2007-08-17 | 2010-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating and diagnosing hematologic malignancies |
JP2011502163A (en) | 2007-10-31 | 2011-01-20 | ザ スクリプス リサーチ インスティテュート | Combination therapies to treat persistent viral infections |
US20100285039A1 (en) | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
EP2262531A1 (en) | 2008-03-08 | 2010-12-22 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
PL2113253T3 (en) | 2008-04-30 | 2010-09-30 | Immatics Biotechnologies Gmbh | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
KR20110074850A (en) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 antagonists and methods of use thereof |
DK2350129T3 (en) | 2008-08-25 | 2015-08-31 | Amplimmune Inc | PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF |
KR20190064664A (en) | 2008-10-02 | 2019-06-10 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | CD86 Antagonist Multi-Target Binding Proteins |
SG10201708690SA (en) | 2008-12-09 | 2017-12-28 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
PL2542590T5 (en) | 2010-03-05 | 2020-08-10 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
-
2001
- 2001-02-28 US US09/794,210 patent/US7030219B2/en not_active Expired - Fee Related
- 2001-04-27 ES ES01928894T patent/ES2330506T3/en not_active Expired - Lifetime
- 2001-04-27 KR KR1020027014537A patent/KR100884766B1/en not_active IP Right Cessation
- 2001-04-27 DE DE60139311T patent/DE60139311D1/en not_active Expired - Lifetime
- 2001-04-27 AT AT01928894T patent/ATE437228T1/en active
- 2001-04-27 CA CA2407680A patent/CA2407680C/en not_active Expired - Fee Related
- 2001-04-27 JP JP2001580357A patent/JP4987208B2/en not_active Expired - Fee Related
- 2001-04-27 EP EP01928894A patent/EP1280900B8/en not_active Expired - Lifetime
- 2001-04-27 DK DK01928894T patent/DK1280900T3/en active
- 2001-04-27 AU AU2001255700A patent/AU2001255700C1/en not_active Ceased
- 2001-04-27 WO PCT/US2001/013430 patent/WO2001083750A2/en active IP Right Grant
- 2001-04-27 MX MXPA02010670A patent/MXPA02010670A/en active IP Right Grant
- 2001-04-27 CN CN2011100702053A patent/CN102199216A/en active Pending
- 2001-04-27 AU AU5570001A patent/AU5570001A/en active Pending
-
2006
- 2006-02-24 US US11/361,057 patent/US7560540B2/en not_active Expired - Fee Related
-
2007
- 2007-10-31 US US11/932,327 patent/US8053414B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/931,653 patent/US8053558B2/en not_active Expired - Fee Related
-
2008
- 2008-05-14 HK HK08105360.3A patent/HK1111726A1/en not_active IP Right Cessation
-
2011
- 2011-05-09 JP JP2011104379A patent/JP5727289B2/en not_active Expired - Fee Related
- 2011-09-23 US US13/243,970 patent/US20120065385A1/en not_active Abandoned
- 2011-09-23 US US13/243,966 patent/US20120065374A1/en not_active Abandoned
-
2013
- 2013-10-31 US US14/068,966 patent/US9370565B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2407680A1 (en) | Dendritic cell co-stimulator molecules | |
US11572388B2 (en) | Chimeric polypeptides and uses thereof | |
US7745215B2 (en) | Methods and compositions for expanding T regulatory cells | |
JP2865300B2 (en) | Human B cell stimulating factor 2 receptor protein | |
US8435494B2 (en) | Mesothelin antibody protein fusions and methods of use | |
KR102044948B1 (en) | Homodimeric protein constructs | |
CN111655716A (en) | IL-15-based fusions with IL-7 and IL-21 | |
CA2383424A1 (en) | Novel b7-4 molecules and uses therefor | |
HU215949B (en) | Process for preparation of purified nucleic-acid sequence corresponding to human gp39, of corresponding soluble gp39, and pharmaceutical composition containing thereof, and promoting of b-cell proliferation | |
JP2004503213A (en) | Single-stranded class I major histocompatibility complex, construct encoding the same and method of producing the same | |
US20230183311A1 (en) | Polypeptide useful in adoptive cell therapy | |
CN115960264A (en) | Transforming growth factor-beta responsive polypeptides and methods of use thereof | |
US20100098719A1 (en) | Fusion Proteins Comprising Two or More IgG Binding Domains of Streptococcal Protein G | |
AU2013263717B2 (en) | Trimeric OX40L-immunoglobulin fusion protein and methods of use | |
EP0706574B1 (en) | Methods for peptide synthesis and purification | |
CA2516834C (en) | Polypeptides and methods for making the same | |
WO1994010304A1 (en) | Marmoset zona pellucida protein zp3 | |
CN116888148A (en) | Peptide markers for tracking genetically engineered cells | |
Kishore et al. | Use of peptide: HLA class II complexes to study specific T cells in autoimmune myasthenia gravis | |
VAN DEN ELSEN et al. | COX TERHORST, BENJAMIN BERKHOUT, BALBINO ALARCON, HANS CLEVERS, KATIA GEORGOPOULOS, DANIEL GOLD, HANS OETTGEN, CAROLYN PETTEY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180427 |